Pomerantz LLP is investigating Celcuity Inc. and its officers for possible securities fraud following the company's announcement of a delayed launch for its FDA-approved breast cancer drug, Revtorpyk. The delay to late Q3 2026 surprised analysts and caused Celcuity's stock to drop 17.6%. The investigation aims to determine if there were unlawful business practices related to the launch delay and stock price impact. Investors affected are encouraged to contact Pomerantz for potential class action participation.
Shopify reported strong Q2 2026 earnings, surpassing analyst expectations thanks to significant growth in AI-driven commerce. AI-driven traffic and orders to Shopify stores tripled year-over-year, boosting confidence in the company's AI innovation. S...
Freightos Limited reported Q2 results surpassing expectations with an EPS of -$0.03 versus -$0.05 expected and record revenue of $7.7 million, driven by a 19% increase in core platform revenue. The company narrowed its adjusted EBITDA loss to $2 mill...
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Rosen Law Firm is investigating a class action lawsuit against Elauwit Connection, Inc. after the company disclosed errors in its 2025 financial statements related to network construction revenue. This disclosure caused Elauwit's stock to drop by 6.8...
Shares of memory and storage chipmakers rose sharply after reports that the US government is urging domestic tech firms to avoid purchasing conventional memory chips from Chinese suppliers. Micron Technology, Sandisk, Western Digital, and Seagate all...
